Upload
hugo-nichols
View
216
Download
2
Tags:
Embed Size (px)
Citation preview
Overview
Founded in 2008 Privately held technology development company Reorganized under new ownership as Tamarisk
Technologies Group in 2014
About Us
Cost effectively increasing the oral bioavailability of existing and emerging drug technologies through better drug delivery design.
Tamarisk’s Value Statement to the Pharmaceutical Industry
Our drug carrier platform utilizes an alginate particle substrate engineered to provide targeted GI delivery. Additional on-board attributes can be added to provide subtle manipulation of targeted local environmental parameters to specifically preserve payload drug activity and energize absorption pathways for increased bioavailability.
MxBATM Delivery SystemTamarisk’s Technology
Oral ingestion is generally viewed by most clinicians as the ideal delivery method and lowers the barriers for patient compliance.
Tamarisk Technologies Group has developed a patent pending oral delivery system that microencapsulates therapeutic agents within a protective substrate that can also contain customizable absorption enhancement agents, such as hydrophobic/hydrophilic stabilizers, receptor ligands, permeation enhancers, excipients, or particle enhancements, such as to optimize particle size and/or solid dispersion.
MxBATM Delivery SystemEnhanced Oral Delivery
Resistant to gastric disintegration Targeted release of the therapeutic payload within the GI
tract Capitalizes on multiple features of the local GI
environment for assisted entry into the bloodstream Provides increased bioavailability of therapeutic payload Reduced GI induced drug degradation Concentrates actives at desired point of absorption Balances the physiochemical properties of the delivery
platform to support optimal transport across the epithelia
MxBATM Delivery SystemBenefits
MxBATM Delivery SystemTamarisk’s Particle
Therapeutic agents successfully encapsulated include:
Ceftriaxone Sodium (Rocephrin) - showed 73% bioavailability in rabbits
Insulin – In vitro tests showed survival in SGF and good elution profile in SIF. Rat enterocyte cell culture tests demonstrated enhanced transport.
Resveratrol – In vivo tests in rats demonstrated significantly shorter Tmax with increased Cmax and AUC compared to controls.
* Note: A complete listing of therapeutic agents encapsulated to date is available upon request.
MxBATM Delivery SystemResults
We believe Tamarisk’s novel particle design is not only an effective solution for various therapeutics we have successfully encapsulated but is the ideal solution as a broad-spectrum platform for orally delivering the most challenging APIs in the industry.
MxBATM Delivery SystemResults
Small Molecules
Peptides
Proteins
Other Functional Molecules
Cyclic Peptides
Monoclonal antibodies
Study conducted by Charles River (Wilmington, MA) Sprague Dawley Rats Oral administration Single dose study
Mean unencapsulated Resveratrol
(20 mg/ml dose)
Tamarisk MxBA encapsulated Resveratrol
(20 mg/ml dose) ChangeAUC0-t ng*h/mL 82.8 312 3.8X increase
Cmax ng*h/mL 82.4 498 6.0X increase
tmax h 1.5 0.5 1 hr faster
MxBATM Delivery SystemResveratrol Pre-Clinical Results
Partnering Opportunity
Tamarisk's unique delivery platform is ready to be entrusted to an effective global leader in the Healthcare industry who's expertise and core values may be combined with our technology to provide the next generation of leading edge therapeutic products.
If your company is looking for the most effective oral delivery system for it's existing pharmaceutical therapies or those in it's pipeline, it's time to consider a new solution. It's time to consider Tamarisk. There's no better time than now for a technology with so much potential to make the world a better place both for us now and for generations to come.
www.tamarisktechgroup.com
Tamarisk’s MxBATM Delivery System opens new avenues of development for new drug technologies in the 21st century. Let Tamarisk custom design a delivery experience for you that is second to none.
Proof of concept test samples can be readily manufactured No additional complex synthesis High encapsulation efficiency Biologic or small molecule capable Hydrophobic or hydrophilic APIs Lab-scale operation ready to go Analytical testing and method development services available
MxBATM Delivery SystemNext Steps
Meet The Team
Dean Crowell | Executive Director
John Connell | Chairman/Director of Corp Development
A.T. Snoots, II | Director, Operations
Darrell Turner | Director, Finance
Who We Are
Tamarisk Technologies Group © 2015All Rights Reserved. No part of this presentation
may be copied, modified, printed, or presented without the author’s permission.
#NoMoreNeedles
Visit us online at
www.tamarisktechgroup.com